Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
CNS Spectr. 2012 Dec;17(4):167-75. doi: 10.1017/S1092852912000624. Epub 2012 Sep 3.
Body dysmorphic disorder (BDD) has a significant impact on the patients' quality of life (QOL). This is an initial literature review of QOL in patients with BDD, examining the extent of QOL impairments, the impact of psychiatric comorbidity on QOL, and the effect of treatment on QOL in BDD. Studies were identified through PubMed, MEDLINE, and PsycINFO searches from 1960-2011 using the keywords: "quality of life," "body dysmorphic disorder," "dysmorphophobia," and "body image." Studies included in this review were selected using specific criteria by two authors reaching consensus. Most BDD research studies have used symptom severity measures mainly to study BDD and its treatments. BBD with or without comorbidities is significantly associated with poor QOL and functioning. Studies show that treatment of BDD, either by psychopharmacological treatments such as selective serotonin reuptake inhibitors (SSRIs) or cognitive behavior therapy, might have positive effects on QOL, although these results need to be replicated in larger studies. In conclusion, QOL could add significant value to the assessment of BDD if used as one of the primary measures in research and clinical work in BDD, by providing more information and clearer understanding on the impact of the illness on satisfaction with activities of daily life and overall sense of wellbeing before and after treatment.
躯体变形障碍（BDD）对患者的生活质量（QOL）有重大影响。本文对 BDD 患者的 QOL 进行了初始文献综述，考察了 QOL 损害的程度、精神共病对 QOL 的影响，以及治疗对 BDD 患者 QOL 的影响。通过在 PubMed、MEDLINE 和 PsycINFO 上使用“生活质量”、“躯体变形障碍”、“畸形恐惧症”和“身体意象”等关键词，从 1960 年至 2011 年进行了文献检索，共检索到 11 篇文献。本综述纳入的研究均采用特定标准，由两位作者达成共识后进行选择。大多数 BDD 研究都使用症状严重程度来衡量 BDD 及其治疗方法。患有或不伴有共病的 BDD 患者与较差的 QOL 和功能显著相关。研究表明，BDD 的治疗，无论是通过选择性 5-羟色胺再摄取抑制剂（SSRIs）等精神药理学治疗，还是认知行为疗法，都可能对 QOL 产生积极影响，但这些结果需要在更大的研究中得到验证。总之，如果将 QOL 作为 BDD 评估的一个主要指标，将其应用于 BDD 的研究和临床工作中，可以提供关于疾病对日常生活活动满意度和整体幸福感的影响的更多信息和更清晰的认识，从而为 BDD 评估增加重要价值。
